Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Licartin plus radiofrequency ablation for prevention of hepatocellular carcinoma recurrence
ChiCTR-TRC-11001684Phase 4Recruiting
- Sponsor
- Air Force Medical University
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of licofelone in hepatocellular carcinoma (HCC) (2 arms), sponsored by Air Force Medical University. Primary endpoints: 1-year survival rate, 2-year survival rate and 10 more. Started Sep 2011; status: recruiting.
02
Drugs
licofelone
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001684.